Innov Clin Neurosci. 2025;22(10–12):14–23. by Samaneh Ghorbani Shirkouhi, MSc; Seyed Sepehr Khatami, MD; Zohair Niroomand, MD; Saeed Sadigh-Eteghad, PhD; Shahrokh Yousefzadeh-Chabok, MD; and Sasan Andalib, PhD Ms. Ghorbani Shirkouhi is
Innov Clin Neurosci. 2025;22(10–12):24–32. by Mark A. Colijn, MD, MSc, FRCPC, UCNS Dr. Colijn is with the Department of Psychiatry, Mathison Centre for Mental Health Research and Education, and Hotchkiss
Innov Clin Neurosci. 2025;22(10–12):33–51. by Franco Di Cesare, MD; Cristiana Di Carlo, MPhil; and Leonardo Di Cesare, MD All authors are with Leoben Research Aurora in San Vincenzo Valle Roveto
Innov Clin Neurosci. 2025;22(10–12):57–71. by Jayant Totlani, DO; Muhammad Arsalan Bashir, MBBS; Laurel Tay, BA; Ashley Ngor, BS; Alexander J. Steiner, PsyD; Drew Hirsch, BS; Lorena Contreras, MA; Sabrina Renteria,
Innov Clin Neurosci. 2025;22(10–12):52–56. by Alexandria Nasr, MD; Larrilyn Grant, MD; Jennifer Golida, BS; and Bailey Hangen, BS, MS All authors are affiliated with the Boonshoft School of Medicine at
Innov Clin Neurosci. 2025;22(10–12):72–77. by Anam Shahid, PhD; Alia Asmat, PhD; and Sunny Singh, MD Dr. Shahid and Dr. Singh are with the Nova Scotia Health Authority in Sydney, Nova
Innov Clin Neur. 2025;22(10–12):78–85. November 2–5, 2025 in Boston, Massachusetts. Artificial intelligence (AI)/machine-based learning Digital phenotyping with real-world data to identify candidates for anti-CGRP migraine treatment Presenters: Giorgio Pietro Biondetti;
Innov Clin Neurosci. 2025;22(10–12):86–87. by Justin Pope, JD Mr. Pope is Associate Director of Risk Management at Professional Risk Management Services (PRMS). FUNDING: No funding was provided for the preparation
Due to the timely nature of this topic, we are providing an advanced release of this article, ahead of the October-December 2025 issue publication. This article is subject to changes
Innov Clin Neurosci. 2025;22(7–9):40–41. by Adil Tumbi, MD; Amit Mistry, MD; BreAnna-Anh Le, BS; and Steven Lippmann, MD Drs. Tumbi and Mistry are with the Oklahoma City Veteran Affairs Health
Innov Clin Neurosci. 2025;22(7–9):42–43. by Akemini “Kem” Isang, RN, JD Ms. Isang is a Risk Manager at Professional Risk Management Services (PRMS). FUNDING: No funding was provided for the preparation
Funding/financial disclosures. The authors have no conflicts of interest relevant to the content of this letter. No funding was received for the preparation of this letter. Innov Clin Neurosci. 2023;20(10–12):8.
by Eirini Beneki, MD, MSc, PhD; Kyriakos Dimitriadis, MD, PhD; Konstantinos Tsatiris, MD, MSc; Konstantina Aggeli, MD, PhD; and Konstantinos Tsioufis, MD, PhD Drs. Beneki, Dimitriadis, Aggeli, and Tsioufis are
by Atmaram Yarlagadda, MD; Kevin Swift, PhD; Nabarun Chakraborty, MS, MBA; Rasha Hammamieh, PhD; Amina Abubakar, PharmD; Marianna Wilbur, PharmD; and Anita H. Clayton, MD Dr. Yarlagadda is Installation Director
by Samara White, PharmD; Tammie Lee Demler, BS, PharmD, MBA, BCGP, BCPP; Eileen Trigoboff, PMHCNS-BC, DNS, DABFN; Lucy Keers, PharmD; and Chloe Matecki, PharmD All authors are with Department of
by Yael Marks, BS, PharmD; Tammie Lee Demler, BS, PharmD, MBA, BCGP, BCPP; and Chloe Matecki, PharmD All authors are with Department of Pharmacy Practice, State University of New York
by Sydnee Akubuiro, MD; Wendy Clay, MPH, MD; Suzie Nelson, MD; and Allison E. Cowan, MD Dr. Akubuiro is with Department of Psychiatry and Behavioral Sciences, Emory University School of
by Joana Jesus-Ribeiro, PhD; Luís Miguel Pires, MS; Ilda Patrícia Ribeiro, PhD; Olinda Rebelo, MD; Ricardo Pereira, MD; Francisco Sales, MD; Isabel Santana, PhD; António Freire, PhD; and Joana Barbosa
